-
Navigating the Future of Preclinical Oncology: Choosing the Right Xenograft Model
Advancing Cancer Research Through Model Selection In the rapidly evolving field of oncology drug discovery, selecting the appropriate preclinical model is more than a technical decision—it is a critical step that determines the translational success of a therapeutic candidate. A recent release highlights the vital importance of standardization and strategic selection across the diverse landscape…
-
Alliance for Genomic Discovery Scales Up: Regeneron Joins, Multiomic Data Initiative Launched
NASDAQ: $ILMN Genomic Research Reaches New Heights with Expansion and Proteomic Integration The landscape of genomic discovery is undergoing a significant transformation with major developments announced by the Alliance for Genomic Discovery (AGD), a collaboration spearheaded by Illumina, Inc. and Nashville Biosciences, LLC (NashBio). Two key announcements signal a massive leap forward: the addition of…
-
Compugen Set to Present at Key Investor Conferences in Early 2026
NASDAQ: $CGEN Compugen Ltd., a clinical-stage company pioneering cancer immunotherapy through advanced AI/ML-powered computational drug target discovery, has announced its management team will be participating in two significant investor conferences in the coming months. These appearances offer an important opportunity for stakeholders to gain insight into the company’s progress across its differentiated pipeline. The first…